Breaking News Instant updates and real-time market news.

2019-12-02 06:55:48 EVFM Evofem $6.08 0.02 (0.33%) 06:55 12/02/19 12/02 06:55 12/02/19 06:55	Evofem announces AMPREVENCE trial meets primary, secondary endpoints Evofem announced top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating the efficacy and safety of Amphora for the prevention of urogenital chlamydia and gonorrhea in women. The study met both its primary and secondary endpoints of reducing the risk of chlamydia and gonorrhea infection, respectively, and demonstrated that Amphora was generally safe and well tolerated. In this study, the infection rate of chlamydia among women who used Amphora for the four-month study period was 4.9% compared to 9.8% among those who used placebo for four months, a relative risk reduction of 50% in the primary endpoint. Among the reported cases of gonorrhea infection, the infection rate was 0.7% in the Amphora arm, compared to 3.2% in the placebo arm, a relative risk reduction of 78% in the secondary endpoint. Amphora was generally safe and well tolerated in this study population, consistent with previous trial results for use of this investigational drug for pregnancy prevention. The number of adverse events was similar across both arms and no serious treatment-related adverse events were reported. Top-line results are based on a preliminary analysis of currently available efficacy and safety data. Further analysis is ongoing and final results are subject to change based on a comprehensive review by the company and the FDA. The company expects to submit full results for presentation at an upcoming scientific meeting. These data will also form the basis for an End-of-Phase 2 meeting request with the FDA.	03 Dec
EVFM Evofem $6.08 0.02 (0.33%) 01/07/19 HCWC 01/07/19 NO CHANGE Target $12.5 HCWC Buy Evofem price target raised to $12.50 from $11 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Evofem Biosciences to $12.50 after the Ampower pivotal trial met its primary endpoint. The results demonstrate that when Amphora is used as directed, the efficacy in which women can have confidence is similar to other frequently-used contraceptive methods, says the analyst. He reiterates a Buy rating on Evofem. 04/12/19 OPCO 04/12/19 NO CHANGE Target $11 OPCO Outperform Evofem price target raised to $11 from $9 at Oppenheimer Oppenheimer analyst Leland Gershell raised his price target for Evofem Biosciences (EVFM) to $11 from $9 following yesterday's announcement of the securities purchase agreement with PDL BioPharma (PDLI), which he says cures a significant financing overhang on favorable terms, mitigates uncertainty around U.S. commercial economics, and provides validation by a well-regarded strategic healthcare investor. He maintains an Outperform rating. 04/12/19 CANT 04/12/19 NO CHANGE Target $9 CANT Overweight Evofem financing removes near-term capital concerns, says Cantor Fitzgerald Cantor Fitzgerald analyst Matthew Lillis believes Evofem Biosciences' (EVFM) financing agreement for up to $80M, including a strategic investment from PDL BioPharma (PDLI), removes near-term capital concerns. Further, it positions Evofem well to execute other pieces of its long-term financing strategy, which may involve sources of non-dilutive capital that could further benefit shareholders, Lillis tells investors in a research note. He reiterates an Overweight rating on the shares with a $9 price target. 10/16/19 CANT 10/16/19 INITIATION Target $9 CANT Overweight Evofem assumed with an Overweight at Cantor Fitzgerald Cantor Fitzgerald analyst Louise Chen assumed coverage of Evofem with an Overweight rating and $9 price target. The market opportunity for the company's Amphora is underappreciated, Chen tells investors in a research note. Amphora could be: a first-in-class hormone-free birth control that also improves sexual satisfaction, says the analyst. She believes now is a good time to take another look at Evofem shares ahead of the Phase 2b trial results in November.

2019-12-02 06:55:48

EVFM

Evofem

$6.08: 0.02 (0.33%)

06:55

12/02/19

12/02

06:55

12/02/19

06:55

Evofem announces AMPREVENCE trial meets primary, secondary endpoints

Evofem announced top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating the efficacy and safety of Amphora for the prevention of urogenital chlamydia and gonorrhea in women. The study met both its primary and secondary endpoints of reducing the risk of chlamydia and gonorrhea infection, respectively, and demonstrated that Amphora was generally safe and well tolerated. In this study, the infection rate of chlamydia among women who used Amphora for the four-month study period was 4.9% compared to 9.8% among those who used placebo for four months, a relative risk reduction of 50% in the primary endpoint. Among the reported cases of gonorrhea infection, the infection rate was 0.7% in the Amphora arm, compared to 3.2% in the placebo arm, a relative risk reduction of 78% in the secondary endpoint. Amphora was generally safe and well tolerated in this study population, consistent with previous trial results for use of this investigational drug for pregnancy prevention. The number of adverse events was similar across both arms and no serious treatment-related adverse events were reported. Top-line results are based on a preliminary analysis of currently available efficacy and safety data. Further analysis is ongoing and final results are subject to change based on a comprehensive review by the company and the FDA. The company expects to submit full results for presentation at an upcoming scientific meeting. These data will also form the basis for an End-of-Phase 2 meeting request with the FDA.

03
Dec

EVFM Evofem

$6.08: 0.02 (0.33%)

01/07/19: HCWC

04/12/19: OPCO

04/12/19: CANT

10/16/19: CANT

TODAY'S FREE FLY STORIES

MRPLY Mr Price Group $0.00 (0.00%) 20:14 12/15/19 12/15 20:14 12/15/19 20:14 Upgrade	Mr Price Group rating change » Mr Price Group upgraded… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
BA Boeing $341.67 -4.795 (-1.38%) 18:48 12/15/19 12/15 18:48 12/15/19 18:48 Periodicals	Boeing considering halting or cutting 737 MAX production, WSJ reports » Boeing (BA) is… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
XEL Xcel Energy $62.27 0.91 (1.48%) 18:42 12/15/19 12/15 18:42 12/15/19 18:42 Initiation	Xcel Energy initiated at Goldman Sachs » Xcel Energy initiated… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AQUA Evoqua Water $19.53 -0.6 (-2.98%) 18:38 12/15/19 12/15 18:38 12/15/19 18:38 Recommendations	Evoqua Water analyst commentary at Stifel » Evoqua Water price target… Evoqua Water price target raised to $22 from $20 at Stifel. Stifel analyst Nathan Jones raised his price target for Evoqua Water to $22 from $20 and keeps a Buy rating on the shares after meeting with management. The analyst came away more confident that the company has "very strong, long-term secular growth drivers" from water outsourcing and upside potential from the emerging per- and polyfluoroalkyl substances threat. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
BLSFY Bluescope Steel $0.00 (0.00%) 18:33 12/15/19 12/15 18:33 12/15/19 18:33 Upgrade	Bluescope Steel rating change at JPMorgan » Bluescope Steel upgraded… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

BLSFY Bluescope Steel $0.00 (0.00%) 16:54 12/15/19 12/15 16:54 12/15/19 16:54 Upgrade	Bluescope Steel rating change at Macquarie » Bluescope Steel upgraded… Bluescope Steel upgraded to Outperform from Neutral at Macquarie. Macquarie analyst Peter Steyn upgraded Bluescope Steel to Outperform from Neutral with a A$16.50 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
SAGE Sage Therapeutics $72.82 0.23 (0.32%) 16:36 12/15/19 12/15 16:36 12/15/19 16:36 Recommendations	Stifel adds Sage to Select List, says SAGE-217 will generate billions » Stifel analyst Paul… Stifel analyst Paul Matteis says his meeting with management of Sage Therapeutics reaffirmed his view that, "though the precise event path is uncertain," the most likely eventual outcome remains that SAGE-217 will ultimately get approved and generate billions in sales. Sage continues to comb through the failed MOUNTAIN study data, and management's view is that a coalescence of factors drove the miss at day 15, Matteis tells investors in a research note. The analyst thinks Sage, after talking with the FDA, will and should initiate additional studies to bolster the SAGE-217 dataset. Despite an "undeniably riskier" story, Matteis added Sage Therapeutics to the Stifel Select List "under the premise that we're one positive trial away from the bull case being back on track." The analyst has a Buy rating on the shares with a $173 price target. The stock closed Friday up 28c to $72.87. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
DD DuPont $64.79 -1.39 (-2.10%) 16:10 12/15/19 12/15 16:10 12/15/19 16:10 Earnings	DuPont sees 2019 operating EBITDA at low end of guidance range » DuPont reconfirms its… DuPont reconfirms its 2019 expectations for total annual revenue of approximately $21.5B and an adjusted EPS range of $3.77 to $3.82. The consensus revenue estimate is $21.58B and earnings per share estimate is $3.81. However, DuPont expects operating EBITDA to be at the low end of the previously provided range, "primarily driven by temporary supply chain disruptions in Safety & Construction and Electronics & Imaging." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
IFF IFF $134.01 -0.55 (-0.41%) 16:07 12/15/19 12/15 16:07 12/15/19 16:07 Earnings	IFF affirms existing 2019 guidance for sales and earnings » IFF is affirming its… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
IFF IFF $134.01 -0.55 (-0.41%) 16:05 12/15/19 12/15 16:05 12/15/19 16:05 Hot Stocks	IFF, DuPont unit see revenue growth in mid-single digits over long term » The company created by… The company created by the merger of IFF (IFF) and DuPont's (DD) Nutrition & Biosciences said it will have: Pro forma revenues of more than $11B based on fiscal year 2019 estimated results; Adjusted EBITDA margin of ~23% pre-synergies and ~26% with run-rate cost synergies based on fiscal 2019 pro forma estimated results; Expected revenue growth rate in the mid-single digits over the long-term; "Strong" cash flow generation supporting an investment grade credit profile; Commitment to the continuation of IFF's historical dividend policy 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

HAS Hasbro $103.99 1.085 (1.05%) , MAT Mattel $13.35 0.58 (4.54%) … 16:03 12/15/19 12/15 16:03 12/15/19 16:03 On The Fly	Week in review: How Trump's policies moved stocks » Catch up on the top… Open Full Text HAS Hasbro $103.99 1.085 (1.05%) MAT Mattel $13.35 0.58 (4.54%) FNKO Funko $15.16 0.23 (1.54%) JAKK JAKKS Pacific $0.94 -0.0244 (-2.54%) BBW Build-A-Bear $2.70 -0.05 (-1.82%) MAS Masco $47.00 -0.44 (-0.93%) FBHS Fortune Brands $65.09 -0.42 (-0.64%) SPY SPDR S&P 500 ETF Trust $317.27 0.13 (0.04%) SPX S&P 500 $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
IFF IFF $134.01 -0.55 (-0.41%) 16:03 12/15/19 12/15 16:03 12/15/19 16:03 Hot Stocks	IFF to merge with DuPont's Nutrition & Biosciences unit via Reverse Morris Trust » IFF (IFF) and DuPont (DD)… IFF (IFF) and DuPont (DD) announced that they have entered into a definitive agreement for the merger of IFF and DuPont's Nutrition & Biosciences business in a Reverse Morris Trust transaction. The deal values the combined company at $45.4B on an enterprise value basis, reflecting a value of $26.2B for the N&B business based on IFF's share price as of December 13. Under the terms of the agreement, which has been unanimously approved by both boards, DuPont shareholders will own 55.4% of the shares of the new company and existing IFF shareholders will own 44.6%. Upon completion of the transaction, DuPont will receive a one-time $7.3B special cash payment, subject to certain adjustments. Upon closing, the new company's board will consist of 13 directors: seven current IFF directors and six DuPont director appointees until the annual meeting in 2022, when there will be six directors from each company. Andreas Fibig will continue to be the Chairman of the Board and an IFF appointee, he will also continue as Chief Executive Officer. The company will be headquartered in New York. DuPont Executive Chairman, Ed Breen, will join the board of the combined company as a DuPont appointee and will serve as Lead Independent Director starting June 1, 2021. IFF expects to realize cost synergies of approximately $300M on a run-rate basis by the end of the third year post-closing. In addition, the combined company's target is to deliver more than $400M in run-rate revenue synergies, which would result in more than $175M of EBITDA. IFF said it is "committed to maintaining an investment grade rating and plans to delever from approximately 4.0x at transaction close to below 3.0x by year two following closing." Following the close of the transaction, IFF expects that "substantially all of the debt of the combined company will be pari passu." IFF and N&B have obtained fully-committed debt financing from Morgan Stanley and Credit Suisse. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
IFF International Flavors $134.01 -0.55 (-0.41%) , DD DuPont $64.79 -1.39 (-2.10%) 15:58 12/15/19 12/15 15:58 12/15/19 15:58 Hot Stocks	Breaking Hot Stocks news story on International Flavors, DuPont » DuPont to receive… IFF International Flavors $134.01 -0.55 (-0.41%) DD DuPont $64.79 -1.39 (-2.10%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
IFF International Flavors $134.01 -0.55 (-0.41%) , DD DuPont $64.79 -1.39 (-2.10%) 15:58 12/15/19 12/15 15:58 12/15/19 15:58 Hot Stocks	Breaking Hot Stocks news story on International Flavors, DuPont » DuPont holders will own… DuPont holders will own 55.4% of combined International Flavors company IFF International Flavors $134.01 -0.55 (-0.41%) DD DuPont $64.79 -1.39 (-2.10%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
IFF International Flavors $134.01 -0.55 (-0.41%) , DD DuPont $64.79 -1.39 (-2.10%) 15:57 12/15/19 12/15 15:57 12/15/19 15:57 Recommendations	International Flavors, DuPont analyst commentary » International Flavors to… IFF International Flavors $134.01 -0.55 (-0.41%) DD DuPont $64.79 -1.39 (-2.10%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

BILL Bill.com $38.59 3.09 (8.70%) , EH Ehang $12.87 0.39 (3.13%) … 15:25 12/15/19 12/15 15:25 12/15/19 15:25 On The Fly	Opening Day: XP finishes first week higher, Sprout Social lower » This past week saw six… Open Full Text BILL Bill.com $38.59 3.09 (8.70%) EH Ehang $12.87 0.39 (3.13%) HCCO Healthcare Merger Corp. $0.00 (0.00%) OCFT OneConnect $10.08 (0.00%) SPT Sprout Social $16.76 (0.00%) XP XP $37.61 3.235 (9.41%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
SNE Sony $67.60 0.285 (0.42%) , SCOR comScore $4.63 -0.41 (-8.13%) … 15:09 12/15/19 12/15 15:09 12/15/19 15:09 Hot Stocks	Sony's 'Jumanji' tops weekend box office with $60.1M in sales » Sony's (SNE)… SNE Sony $67.60 0.285 (0.42%) SCOR comScore $4.63 -0.41 (-8.13%) DIS Disney $146.37 0.4 (0.27%) LGF.A Lionsgate $9.68 -0.315 (-3.15%) LGF.B Lionsgate $9.00 -0.35 (-3.74%) T AT&T $38.24 -0.11 (-0.29%) CMCSA Comcast $43.59 0.57 (1.33%) CMCSK Comcast $0.00 (0.00%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Jan 29 Jan
DLTR Dollar Tree $93.59 1.04 (1.12%) , DG Dollar General $154.75 -0.885 (-0.57%) 14:31 12/15/19 12/15 14:31 12/15/19 14:31 Periodicals	Local governments want dollar stores selling fresh food, WSJ reports » Local governments across… Local governments across the U.S. are placing zoning limits on discount stores, and requiring them to set aside space for fresh food, Talal Ansari of Wall Street Journal reports. Oklahoma City this week is scheduled to hold a public hearing on a plan requiring new retailers in the area to designate at least 500 square feet of space to fresh food, Ansari points out. The dollar store space is dominated by Dollar Tree (DLTR), which bought Family Dollar in 2015, and Dollar General (DG). Dollar General isn't and never intended to be a grocery store, but every store offers its customers essentials such as eggs, milk and bread, its spokeswoman Crystal Ghassemi told the Journal. By January 2020, 650 Dollar General locations, or about 4.6% of the company's more than 14,000 stores, will sell produce, she added. Dollar Tree and Family Dollar offer a "broad range of basic essentials to families at low prices they can afford," said a spokesman, and don't intend to be grocery stores. Reference Link DLTR Dollar Tree $93.59 1.04 (1.12%) DG Dollar General $154.75 -0.885 (-0.57%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ELUXY Electrolux $0.00 (0.00%) 14:25 12/15/19 12/15 14:25 12/15/19 14:25 Hot Stocks	Electrolux sees $70M charge in Q4 from North America consolidation » Electrolux provided an… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
BCS Barclays $9.74 0.655 (7.21%) , BP BP $36.95 -0.005 (-0.01%) … 10:39 12/15/19 12/15 10:39 12/15/19 10:39 Recommendations	Barclays, BP, Amadeus IT Group, Anglo American, BT Group, Carlsberg, Demant, E.ON, Intertek, Novartis, Persimmon, Puma, RSA Insurance, Koninklijke Vopak, Hammerson, NMC Health, Reckitt Benckiser, Renault analyst commentary » Jefferies gives European… Jefferies gives European investors 'Christmas list of 20 stocks for 2020'. Analysts at Jefferies presented a European "Christmas list of 20 stocks for 2020." There are 10 large cap buys, five mid-cap buys and five stocks that the firm thinks will underperform. The list of buys are Amadeus IT Group (AMADY), Anglo American (NGLOY), Barclays (BCS), BP (BP), BT Group (BT), Carlsberg (CABGY), Demant (WILYY), E.ON (EONGY), Intermediate Capital, Intertek (IKTSY), Novartis (NVS), Persimmon (PSMMY), Puma (PUMSY), RSA Insurance (RSNAY) and Koninklijke Vopak (VOPKY). The five European stocks that Jefferies thinks will underperform in 2020 are Hammerson (HMSNF), NMC Health (NMHLY), Reckitt Benckiser (RBGLY), Renault (RNLSY) and Securitas. BCS Barclays $9.74 0.655 (7.21%) BP BP $36.95 -0.005 (-0.01%) AMADY Amadeus IT Group $0.00 (0.00%) NGLOY Anglo American $0.00 (0.00%) BT BT Group $0.00 (0.00%) CABGY Carlsberg $0.00 (0.00%) WILYY Demant $0.00 (0.00%) EONGY E.ON $0.00 (0.00%) IKTSY Intertek $0.00 (0.00%) NVS Novartis $93.00 -0.055 (-0.06%) PSMMY Persimmon $0.00 (0.00%) PUMSY Puma $0.00 (0.00%) RSNAY RSA Insurance $0.00 (0.00%) VOPKY Koninklijke Vopak $0.00 (0.00%) HMSNF Hammerson $0.00 (0.00%) NMHLY NMC Health $0.00 (0.00%) RBGLY Reckitt Benckiser $0.00 (0.00%) RNLSY Renault $0.00 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Dec 23 Mar

SNE Sony $67.60 0.285 (0.42%) , SCOR comScore $4.63 -0.41 (-8.13%) … 05:55 12/15/19 12/15 05:55 12/15/19 05:55 Hot Stocks	Sony's 'Jumanji' tops weekend box office with $60.1M in sales » Sony's (SNE)… SNE Sony $67.60 0.285 (0.42%) SCOR comScore $4.63 -0.41 (-8.13%) DIS Disney $146.37 0.4 (0.27%) LGF.A Lionsgate $9.68 -0.315 (-3.15%) LGF.B Lionsgate $9.00 -0.35 (-3.74%) T AT&T $38.24 -0.11 (-0.29%) CMCSA Comcast $43.59 0.57 (1.33%) CMCSK Comcast $0.00 (0.00%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Jan 29 Jan
AOBC American Outdoor Brands $9.23 -0.04 (-0.43%) , AVCO Avalon GloboCare $2.27 -0.06 (-2.58%) … 04:55 12/15/19 12/15 04:55 12/15/19 04:55 Conference/Events	Roth Capital to hold a conference » 8th Annual ROTH Deer… AOBC American Outdoor Brands $9.23 -0.04 (-0.43%) AVCO Avalon GloboCare $2.27 -0.06 (-2.58%) BBSI Barrett Business $93.18 1.82 (1.99%) BNGO Bionano Genomics $1.02 0.01 (0.99%) IRMD iRadimed $25.25 -0.52 (-2.02%) FC Franklin Covey $35.21 -0.57 (-1.59%) NBEV New Age Beverages $1.91 -0.015 (-0.78%) WATT Energous $1.99 (0.00%) EAST Eastside Distilling $2.79 -0.12 (-4.12%) DCTH Delcath Systems $0.00 (0.00%) BOOM DMC Global $52.89 0.64 (1.22%) CLAR Clarus $13.47 -0.02 (-0.15%) JRSH Jerash Holdings $6.46 (0.00%) MCHX Marchex $3.68 0.03 (0.82%) JYNT Joint Corp. $17.37 0.28 (1.64%) SOLY Soliton $10.35 -0.005 (-0.05%) SMSI Smith Micro $4.66 0.095 (2.08%) PWFL PowerFleet $6.10 0.05 (0.83%) OSIS OSI Systems $100.60 0.63 (0.63%) LOVE Lovesac $10.80 -1.01 (-8.55%) VERI Veritone $2.73 -0.1 (-3.53%) WTER Alkaline Water $1.09 -0.01 (-0.91%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Dec 19 Dec 23 Jan 23 Jan 24 Jan 29 Jan
PNC PNC Financial $158.60 -0.3 (-0.19%) , PYPL PayPal $107.68 2.01 (1.90%) 13:57 12/14/19 12/14 13:57 12/14/19 13:57 Periodicals	PNC clients having trouble connecting to PayPal's Venmo, WSJ reports » Many of PNC… Many of PNC Financial's (PNC) clients are having trouble connecting their accounts to PayPal's (PYPL) Venmo app, highlighting the rivalry between the banking industry and financial technology companies, Yuka Hayashi of Wall Street Journal reports. When the customers have sought help, they have found the two companies blaming each other for the disruption, Hayashi says. Reference Link PNC PNC Financial $158.60 -0.3 (-0.19%) PYPL PayPal $107.68 2.01 (1.90%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	18 Dec 15 Jan
BRK.A Berkshire Hathaway $338,250.51 -992.49 (-0.29%) , CMCSA Comcast $43.59 0.57 (1.33%) … 07:44 12/14/19 12/14 07:44 12/14/19 07:44 Periodicals	Berkshire, Anthem among Barron's top 10 stock picks for 2020 » Barron's has… Barron's has identified 10 top stocks for 2020 with a tilt toward value names, Andrew Bary writes in this weekend's magazine. The list is made up of Berkshire Hathaway (BRK.A), Comcast (CMCSA), Royal Dutch Shell (RDS.B), Pfizer (PFE), ViacomCBS (VIAC), Anthem (ANTM), Dell Technologies (DELL), Alphabet (GOOGL), Amerco (UHAL) and United Technologies (UTX). The group has an average projected 2020 price to earnings ratio of 14, against 18 for the S&P 500, with an average dividend yield is 1.8%, Bary points out. Reference Link BRK.A Berkshire Hathaway $338,250.51 -992.49 (-0.29%) CMCSA Comcast $43.59 0.57 (1.33%) RDS.B Royal Dutch Shell $57.41 -0.19 (-0.33%) RDS.A Royal Dutch Shell $57.44 -0.32 (-0.55%) PFE Pfizer $38.31 -0.23 (-0.60%) VIAC ViacomCBS $38.62 0.83 (2.20%) ANTM Anthem $284.14 -0.405 (-0.14%) DELL Dell Technologies $49.39 -0.11 (-0.22%) GOOG Alphabet $1,348.07 -2.09 (-0.15%) GOOGL Alphabet Class A $1,347.11 -1.4 (-0.10%) UHAL Amerco $360.28 7.57 (2.15%) UTX United Technologies $148.99 -0.5 (-0.33%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Jan 27 Feb
PCG PG&E $11.26 -0.49 (-4.17%) 07:38 12/14/19 12/14 07:38 12/14/19 07:38 Hot Stocks	California Governor says PG&E restructuring plan 'falls woefully short' » California Governor Gavin… California Governor Gavin Newsom late Friday rejected PG&E's plan to pay Northern California wildfire victims and exit bankruptcy. In a letter to PG&E Chief Executive Bill Johnson, the governor declared that the company's proposal "falls woefully short" of a law outlining requirements that would allow the utility to receive state assistance. He states, "The resolution of this bankruptcy must yield a radically restructured and transformed utility that is responsible and accountable." Among other things, Newsom demanded an entirely new slate of directors who are subject to state approval, and a structure that would allow PG&E's operating license to be transferred "to the state or a third-party when circumstances warrant." Newsom added, "For too long, PG&E has been mismanaged, failed to make adequate investments in fire safety and fire prevention, and neglected critical infrastructure. PG&E has simply violated the public trust." Shares of PG&E closed Friday down 48c to $11.24. Reference Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan

Events

Earnings calls, analyst events, roadshows and more

OKTA ...
Tomorrow at 00:00

17th Semi-Annual Silicon Valley Technology Bus Tour Conferences

Silicon Valley, CA
Tomorrow at 00:00

Greater China Tourism/Consumer Tour Conferences

Taipei, Beijing
VCYT
Tomorrow at 00:00

Veracyte Firm Sponsored Meetings

Boston, MA
GWPH
Tomorrow at 00:00

GW Pharmaceuticals Firm Sponsored Meetings

Europe
FELE
Tomorrow at 00:00

Franklin Electric Firm Sponsored Meetings

New York, NY
DL
Tomorrow at 00:00

China Distance Education Firm Sponsored Meetings

New York, NY
VBLT
Tomorrow at 00:00

VBL Therapeutics Firm Sponsored Meetings

New York, NY
TXN
Tomorrow at 00:00

Texas Instruments Firm Sponsored Meetings

New York, NY
PD
Tomorrow at 00:00

PagerDuty Firm Sponsored Meetings

New York, NY
KOP
Tomorrow at 00:00

Koppers Holdings Firm Sponsored Meetings

West Coast

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	RIBT X RIBT RiceBran Secondary Managers: LAKE $2.19
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Evofem announces AMPREVENCE trial meets primary, secondary endpoints

TODAY'S FREE FLY STORIES

Get Full Fly Access